Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 328-336

  Erdem Eraslan, Lale ^a   Gravendeel, Lonneke A ^a   De Rooi, Johan ^a   Eilers, Paul H C ^a   Idbaih, Ahmed ^g   Spliet, Wim G M ^b   Den Dunnen, Wilfred F A ^c   Teepen, Johannes L ^d   Wesseling, Pieter ^e,f   Smitt, Peter A E Sillevis ^a   Kros, Johan M ^a   Gorlia, Thierry ^h   Van Den Bent, Martin J ^a   French, Pim J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CPRLab   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; FEMALE; GENE EXPRESSION PROFILING; GLIOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; PROGNOSIS; TRANSCRIPTOME; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84873362485     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.1444     Document Type: Article

References (39)

1. Valk PJ, Verhaak RG, Beijen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628, 2004 (Pubitemid 38528701)
2. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
3. Northcott PA, Korshunov A, Witt H, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
4. French PJ, Peeters J, Horsman S, et al: Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67:5635-5642, 2007 (Pubitemid 46984994)
5. French PJ, Swagemakers SM, Nagel JH, et al: Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 65:11335-11344, 2005 (Pubitemid 41821690)
6. Nutt CL, Mani DR, Betensky RA, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607, 2003 (Pubitemid 36373650)
7. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006 (Pubitemid 43357943)
8. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69:9065-9072, 2009
9. Li A, Walling J, Ahn S, et al: Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69:2091-2099, 2009
10. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
11. Masuda N, Ohnishi T, Kawamoto S, et al: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 27:4436-4443, 1999 (Pubitemid 29533185)
12. Hoshida Y, Villanueva A, Kobayashi M, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995-2004, 2008
13. Hall JS, Leong HS, Armenoult LS, et al: Exonarray profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffinembedded tumour samples. Br J Cancer 104:971-981, 2011
14. Linton KM, Hey Y, Saunders E, et al: Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalinfixed paraffin-embedded tumours. Br J Cancer 98:1403-1414, 2008 (Pubitemid 351543581)
15. Gravendeel LA, de Rooi JJ, Eilers PH, et al: Gene expression profiles of gliomas in formalinfixed paraffin-embedded material. Br J Cancer 106:538-545, 2012
16. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
17. van den Bent MJ, Gravendeel LA, Gorlia T, et al: A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. Clin Cancer Res 17:7148-7155, 2011
18. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998 (Pubitemid 28482012)
19. van den Bent MJ, Looijenga LH, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003 (Pubitemid 36237315)
20. van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol [epub ahead of print on October 15, 2012]
21. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomstine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006 (Pubitemid 46630567)
22. Kouwenhoven MC, Gorlia T, Kros JM, et al: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11:737-746, 2009
23. Idbaih A, Dalmasso C, Kouwenhoven M, et al: Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol 103:221-230, 2011
24. Kapp AV, Tibshirani R: Are clusters found in one dataset present in another dataset? Biostatistics 8:9-31, 2007 (Pubitemid 44906101)
25. Heinze G, Schemper M: Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 71:155-163, 2003 (Pubitemid 36577651)
26. Schemper M, Henderson R: Predictive accuracy and explained variation in Cox regression. Biometrics 56:249-255, 2000 (Pubitemid 30165116)
27. Dunkler D, Michiels S, Schemper M: Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43:745-751, 2007 (Pubitemid 46502906)
28. van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604, 2010
29. Kros JM, Gorlia T, Kouwenhoven MC, et al: Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007 (Pubitemid 46869696)
30. Freije WA, Castro-Vargas FE, Fang Z, et al: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503-6510, 2004 (Pubitemid 39297907)
31. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007 (Pubitemid 47103521)
32. Madhavan S, Zenklusen JC, Kotliarov Y, et al: Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7:157-167, 2009
33. Shirahata M, Iwao-Koizumi K, Saito S, et al: Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 13:7341-7356, 2007
34. Shirahata M, Oba S, Iwao-Koizumi K, et al: Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci 100:165-172, 2009
35. Idbaih A, Kouwenhoven M, Jeuken J, et al: Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology 28:440-443, 2008 (Pubitemid 351798971)
36. Kouwenhoven MC, Kros JM, French PJ, et al: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499-2503, 2006 (Pubitemid 44468379)
37. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
38. Cairncross G, Wang M, Shaw E, et al: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol [epub ahead of print on Oct. 15, 2012]
39. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015-3024, 2008